We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Immunomedics Inc | NASDAQ:IMMU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 87.86 | 88.00 | 83.47 | 0 | 01:00:00 |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 12 | | | |
| | | | 39 | | | |
| | | | 39 | | | |
| | | | 39 | | | |
| | | | 40 | | | |
| | | | 46 | | |
Name of Executive Officer
|
| |
Position
|
|
Dr. Behzad Aghazadeh | | | Executive Chairman | |
Kurt Andrews | | | Chief Human Resources Officer | |
Bryan Ball | | | Chief Quality Officer | |
Brendan Delaney | | | Chief Commercial Officer | |
Jared Freedberg | | | General Counsel/Corporate Secretary | |
Dr. Loretta Itri | | | Chief Medical Officer | |
Usama Malik | | |
Chief Financial Officer/Chief Business Officer
|
|
Name of Executive Officer or Director
|
| |
Number of
Shares(1) |
| |
Aggregate Cash
Consideration for Shares ($) |
| ||||||
Dr. Behzad Aghazadeh
|
| | | | 26,263,516 | | | | | | 2,311,189,408 | | |
Robert Azelby
|
| | | | — | | | | | | — | | |
Dr. Charles Baum
|
| | | | 9,667 | | | | | | 850,696 | | |
Scott Canute
|
| | | | 13,516 | | | | | | 1,189,408 | | |
Barbara G. Duncan
|
| | | | 49,244 | | | | | | 4,333,472 | | |
Peter Barton Hutt
|
| | | | 13,516 | | | | | | 1,189,408 | | |
Name of Executive Officer or Director
|
| |
Number of
Shares(1) |
| |
Aggregate Cash
Consideration for Shares ($) |
| ||||||
Dr. Khalid Islam
|
| | | | 13,516 | | | | | | 1,189,408 | | |
Bryan Ball
|
| | | | 10,000 | | | | | | 880,000 | | |
Brendan Delaney
|
| | | | — | | | | | | — | | |
Usama Malik
|
| | | | 18,856 | | | | | | 1,659,328 | | |
All of the Company’s current directors and
executive officers as a group (13 persons) |
| | | | 26,406,831 | | | | | | 2,323,801,128 | | |
| | |
Vested Company Options
|
| |
Unvested Company Options
|
| |
Aggregate Outstanding
Company Options |
| |||||||||||||||||||||||||||||||||
Name of Executive
Officer or Director |
| |
Shares
Underlying Vested Company Options |
| |
Weighted
Average Exercise Price ($) |
| |
Aggregate
Vested Company Option Payment ($)(1) |
| |
Shares
Underlying Unvested Company Options |
| |
Weighted
Average Exercise Price ($) |
| |
Aggregate
Unvested Company Option Payment ($)(1) |
| |
Aggregate
Company Option Payment ($)(1) |
| |||||||||||||||||||||
Dr. Behzad Aghazadeh
|
| | | | 196,074 | | | | | | 16.97 | | | | | | 13,926,914 | | | | | | 6,540 | | | | | | 33.62 | | | | | | 355,645 | | | | | | 14,282,559 | | |
Bryan Ball
|
| | | | 70,441 | | | | | | 16.15 | | | | | | 5,061,465 | | | | | | 191,496 | | | | | | 16.12 | | | | | | 13,765,564 | | | | | | 18,827,029 | | |
Brendan Delaney
|
| | | | 177,395 | | | | | | 14.71 | | | | | | 13,000,925 | | | | | | 213,065 | | | | | | 15.94 | | | | | | 15,354,228 | | | | | | 28,355,153 | | |
Usama Malik
|
| | | | 157,774 | | | | | | 15.12 | | | | | | 11,498,319 | | | | | | 228,306 | | | | | | 16.45 | | | | | | 16,334,332 | | | | | | 27,832,651 | | |
Other Executive
Officers as a group (3 persons) |
| | | | 187,421 | | | | | | 19.16 | | | | | | 12,901,831 | | | | | | 530,756 | | | | | | 17.64 | | | | | | 37,345,063 | | | | | | 50,246,893 | | |
Non-Employee Directors as a group
(6 persons) |
| | | | 280,471 | | | | | | 13.67 | | | | | | 20,848,448 | | | | | | 61,740 | | | | | | 27.33 | | | | | | 3,745,771 | | | | | | 24,594,219 | | |
| | |
Unvested Company RSUs
|
| |||||||||
| | |
Shares Underlying
Unvested Company RSUs |
| |
Aggregate Unvested Company
RSU Payment ($)(1) |
| ||||||
Dr. Behzad Aghazadeh
|
| | | | 103,718 | | | | | | 9,127,184 | | |
Non-Employee Directors as a group (6 persons)
|
| | | | 22,308 | | | | | | 1,963,104 | | |
| | |
Golden Parachute Compensation Table
|
| |||||||||||||||||||||||||||
Named Executive Officer
|
| |
Cash ($)(1)
|
| |
Equity ($)(2)
|
| |
Perquisites/Benefits
($)(3) |
| |
Tax
Reimbursement ($)(4) |
| |
Total ($)
|
| |||||||||||||||
Dr. Behzad Aghazadeh
|
| | | | — | | | | | | 9,482,829 | | | | | | — | | | | | | 886,556 | | | | | | 10,369,385 | | |
Bryan Ball
|
| | | | 800,000 | | | | | | 13,765,564 | | | | | | 33,440 | | | | | | 1,514,672 | | | | | | 16,113,676 | | |
Brendan Delaney
|
| | | | 913,750 | | | | | | 15,354,228 | | | | | | 33,440 | | | | | | 1,562,566 | | | | | | 17,863,984 | | |
Usama Malik
|
| | | | 956,250 | | | | | | 16,118,938 | | | | | | 10,906 | | | | | | 1,643,131 | | | | | | 18,729,225 | | |
Harout Semerjian(5)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Morris Rosenberg(5)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Michael Pehl(5)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Named Executive Officer
|
| |
Base Salary
Component of Severance ($) |
| |
Bonus Component of
Severance ($) |
| |
2020 Annual Bonus
(Merger Agreement) ($) |
| |
Total ($)
|
| ||||||||||||
Dr. Behzad Aghazadeh
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Bryan Ball
|
| | | | 400,000 | | | | | | 160,000 | | | | | | 240,000 | | | | | | 800,000 | | |
Brendan Delaney
|
| | | | 430,000 | | | | | | 193,500 | | | | | | 290,250 | | | | | | 913,750 | | |
Usama Malik
|
| | | | 450,000 | | | | | | 202,500 | | | | | | 303,750 | | | | | | 956,250 | | |
Harout Semerjian
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Morris Rosenberg
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Michael Pehl
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Named Executive Officer
|
| |
Value of Company
Options ($) |
| |
Value of Company
RSUs ($) |
| |
Total
Value ($) |
| |||||||||
Dr. Behzad Aghazadeh
|
| | | | 355,645 | | | | | | 9,127,184 | | | | | | 9,482,829 | | |
Bryan Ball
|
| | | | 13,765,564 | | | | | | — | | | | | | 13,765,564 | | |
Brendan Delaney
|
| | | | 15,354,228 | | | | | | — | | | | | | 15,354,228 | | |
Usama Malik
|
| | | | 16,118,938 | | | | | | — | | | | | | 16,118,938 | | |
Harout Semerjian
|
| | | | — | | | | | | — | | | | | | — | | |
Morris Rosenberg
|
| | | | — | | | | | | — | | | | | | — | | |
Michael Pehl
|
| | | | — | | | | | | — | | | | | | — | | |
| | |
Fiscal Year Ending December 31,
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
2020E
|
| |
2021E
|
| |
2022E
|
| |
2023E
|
| |
2024E
|
| |
2025E
|
| |
2026E
|
| |
2027E
|
| |
2028E
|
| |
2029E
|
| |
2030E
|
| |
2031E
|
| |
2032E
|
| |
2033E
|
| |
2034E
|
| | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total Net Revenue
|
| | | $ | 187 | | | | | $ | 823 | | | | | $ | 1,522 | | | | | $ | 2,239 | | | | | $ | 3,612 | | | | | $ | 4,673 | | | | | $ | 5,715 | | | | | $ | 6,489 | | | | | $ | 7,026 | | | | | $ | 7,395 | | | | | $ | 7,694 | | | | | $ | 7,913 | | | | | $ | 8,115 | | | | | $ | 8,347 | | | | | $ | 5,969 | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||
Memo: Total Net Revenue Excl. One-Time Everest Milestones(1)
|
| | | $ | 187 | | | | | $ | 758 | | | | | $ | 1,522 | | | | | $ | 2,219 | | | | | $ | 3,586 | | | | | $ | 4,658 | | | | | $ | 5,695 | | | | | $ | 6,489 | | | | | $ | 7,001 | | | | | $ | 7,395 | | | | | $ | 7,694 | | | | | $ | 7,913 | | | | | $ | 8,115 | | | | | $ | 8,347 | | | | | $ | 5,969 | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||
Memo: Total Net
Revenue Incl. Outbound RP/TSRI Royalties(2) |
| | | $ | 177 | | | | | $ | 787 | | | | | $ | 1,452 | | | | | $ | 2,141 | | | | | $ | 3,475 | | | | | $ | 4,521 | | | | | $ | 5,552 | | | | | $ | 6,314 | | | | | $ | 6,843 | | | | | $ | 7,206 | | | | | $ | 7,499 | | | | | $ | 7,714 | | | | | $ | 7,913 | | | | | $ | 8,141 | | | | | $ | 5,969 | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||
Gross Profit
|
| | | $ | 166 | | | | | $ | 702 | | | | | $ | 1,260 | | | | | $ | 1,949 | | | | | $ | 3,276 | | | | | $ | 4,257 | | | | | $ | 5,209 | | | | | $ | 5,912 | | | | | $ | 6,398 | | | | | $ | 6,735 | | | | | $ | 7,009 | | | | | $ | 7,210 | | | | | $ | 7,398 | | | | | $ | 7,613 | | | | | $ | 5,579 | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||
Total R&D Expense
|
| | | $ | (231) | | | | | $ | (273) | | | | | $ | (377) | | | | | $ | (494) | | | | | $ | (446) | | | | | $ | (533) | | | | | $ | (592) | | | | | $ | (671) | | | | | $ | (696) | | | | | $ | (702) | | | | | $ | (694) | | | | | $ | (667) | | | | | $ | (630) | | | | | $ | (589) | | | | | $ | (409) | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||
Total S&M Expense
|
| | | $ | (57) | | | | | $ | (112) | | | | | $ | (166) | | | | | $ | (208) | | | | | $ | (368) | | | | | $ | (442) | | | | | $ | (554) | | | | | $ | (647) | | | | | $ | (686) | | | | | $ | (709) | | | | | $ | (721) | | | | | $ | (716) | | | | | $ | (702) | | | | | $ | (689) | | | | | $ | (489) | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||
Total G&A Expense
|
| | | $ | (54) | | | | | $ | (107) | | | | | $ | (213) | | | | | $ | (271) | | | | | $ | (353) | | | | | $ | (363) | | | | | $ | (446) | | | | | $ | (501) | | | | | $ | (531) | | | | | $ | (549) | | | | | $ | (558) | | | | | $ | (557) | | | | | $ | (549) | | | | | $ | (542) | | | | | $ | (425) | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||
EBIT(3) | | | | $ | (176) | | | | | $ | 210 | | | | | $ | 504 | | | | | $ | 976 | | | | | $ | 2,110 | | | | | $ | 2,918 | | | | | $ | 3,617 | | | | | $ | 4,093 | | | | | $ | 4,486 | | | | | $ | 4,775 | | | | | $ | 5,035 | | | | | $ | 5,270 | | | | | $ | 5,516 | | | | | $ | 5,793 | | | | | $ | 4,256 | | | | | | | | | | | | | | | | |
| | |
Fiscal Year Ending December 31,
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
2020E
|
| |
2021E
|
| |
2022E
|
| |
2023E
|
| |
2024E
|
| |
2025E
|
| |
2026E
|
| |
2027E
|
| |
2028E
|
| |
2029E
|
| |
2030E
|
| |
2031E
|
| |
2032E
|
| |
2033E
|
| |
2034E
|
| | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unlevered Free
Cash Flow(1) |
| |
$(197) for FY’20/
$(49) for Q4’20
|
| | | $ | 143 | | | | | $ | 362 | | | | | $ | 721 | | | | | $ | 1,580 | | | | | $ | 2,201 | | | | | $ | 2,735 | | | | | $ | 3,099 | | | | | $ | 3,401 | | | | | $ | 3,624 | | | | | $ | 3,825 | | | | | $ | 4,008 | | | | | $ | 4,199 | | | | | $ | 4,414 | | | | | $ | 3,229 | | | | | | | | | | | | | | | | |
| | |
2024E
EV/Revenue Multiple |
| |||
• Alnylam Pharmaceuticals, Inc.
|
| | | | 5.0x | | |
• argenx SE
|
| | | | 4.7x | | |
• BioMarin Pharmaceutical Inc.
|
| | | | 3.6x | | |
• Genmab A/S*
|
| | | | 8.7x | | |
• Incyte Corporation
|
| | | | 3.8x | | |
• Neurocrine Biosciences, Inc.
|
| | | | 3.8x | | |
• Sarepta Therapeutics, Inc.
|
| | | | 2.9x | | |
• Seattle Genetics, Inc.
|
| | | | 6.1x | | |
Median | | | | | 3.8x | | |
|
Date
Announced |
| |
Target
|
| |
Acquiror
|
| |
Transaction Value/Four-Year
Forward Revenue Multiple |
|
|
06/17/2019
|
| | Array BioPharma Inc. | | | Pfizer Inc. | | |
9.5x
|
|
|
01/07/2019
|
| | Loxo Oncology, Inc. | | | Eli Lilly and Company | | |
10.7x
|
|
|
12/03/2018
|
| | TESARO, Inc. | | | GlaxoSmithKline plc | | |
5.7x
|
|
|
04/09/2018
|
| | AveXis, Inc. | | | Novartis AG | | |
12.7x
|
|
|
08/28/2017
|
| | Kite Pharma, Inc. | | | Gilead Sciences, Inc. | | |
10.7x
|
|
|
08/22/2016
|
| | Medivation, Inc. | | | Pfizer Inc. | | |
7.8x
|
|
|
03/04/2015
|
| | Pharmacyclics, Inc. | | | AbbVie Inc. | | |
7.1x
|
|
|
08/25/2013
|
| | Onyx Pharmaceuticals, Inc. | | | Amgen Inc. | | |
4.7x
|
|
| | |
Transaction Value/Revenue Multiple
Implied Four-Year Forward Revenue Multiple |
| |||
Median
|
| | | | 8.6x | | |
Selected Companies
|
| |
2024 PoS Adjusted Public
Company Revenue Multiples |
| |||
ACADIA Pharmaceuticals Inc.
|
| | | | 2.34x | | |
Agios Pharmaceuticals, Inc.
|
| | | | 2.21x | | |
BeiGene, Ltd.
|
| | | | 6.83x | | |
Deciphera Pharmaceuticals, Inc.
|
| | | | 2.97x | | |
Epizyme, Inc.
|
| | | | 1.65x | | |
Genmab A/S
|
| | | | 8.32x | | |
Global Blood Therapeutics, Inc.
|
| | | | 2.29x | | |
Incyte Corporation
|
| | | | 3.77x | | |
MorphoSys AG
|
| | | | 3.31x | | |
Sarepta Therapeutics, Inc.
|
| | | | 3.40x | | |
Seattle Genetics, Inc.
|
| | | | 5.90x | | |
|
Implied Per Share Equity Value Reference Range for the Company
|
| |
Consideration
|
| |||
|
$47.85 – $76.90
|
| | | $ | 88.00 | | |
Acquiror
|
| |
Target
|
| |
CY+4 PoS Adjusted
Transaction Revenue Multiples |
|
AbbVie Inc. | | | Pharmacyclics, Inc. | | |
4.28x
|
|
Amgen Inc. | | | Onyx Pharmaceuticals, Inc. | | |
4.29x
|
|
Eli Lilly and Company | | | Loxo Oncology, Inc. | | |
10.46x
|
|
Gilead Sciences, Inc. | | | Kite Pharma, Inc. | | |
5.40x
|
|
GlaxoSmithKline plc | | | TESARO, Inc. | | |
3.45x
|
|
Novartis AG | | | AveXis, Inc. | | |
7.34x
|
|
Pfizer Inc. | | | Array BioPharma Inc. | | |
9.89x
|
|
Pfizer Inc. | | | Medivation, Inc. | | |
5.64x
|
|
|
Implied Per Share Equity Value Reference Range for the Company
|
| |
Consideration
|
| |||
|
$68.20 – $100.15
|
| | | $ | 88.00 | | |
|
Implied Per Share Equity Value
Reference Range for the Company |
| |
Consideration
|
| |||
|
$77.15 – $96.10
|
| | | $ | 88.00 | | |
Name
|
| |
Date of
Transaction |
| |
Nature of Transaction
|
| |
Number of
Shares |
| |
Price Per
Share ($) |
| |||||||||
Barbara Gayle Duncan
|
| | | | 8/12/2020 | | | |
Exercise of stock options
|
| | | | 17,077 | | | | | | 12.93 | | |
Barbara Gayle Duncan
|
| | | | 8/17/2020 | | | |
Exercise of stock options
|
| | | | 20,000 | | | | | | 16.96 | | |
Barbara Gayle Duncan
|
| | | | 9/14/2020 | | | |
Exercise of stock options
|
| | | | 2,500 | | | | | | 16.96 | | |
Morris Rosenberg
|
| | | | 7/28/20 | | | |
Exercise of stock options
|
| | | | 7,500 | | | | | | 8.70 | | |
Morris Rosenberg
|
| | | | 7/28/20 | | | |
Exercise of stock options
|
| | | | 7,500 | | | | | | 8.70 | | |
Morris Rosenberg
|
| | | | 7/28/20 | | | |
Exercise of stock options
|
| | | | 7,500 | | | | | | 8.70 | | |
Morris Rosenberg
|
| | | | 7/28/20 | | | |
Exercise of stock options
|
| | | | 10,690 | | | | | | 17.94 | | |
Morris Rosenberg
|
| | | | 7/30/20 | | | |
Exercise of stock options
|
| | | | 7,000 | | | | | | 22.27 | | |
Morris Rosenberg
|
| | | | 7/30/20 | | | |
Exercise of stock options
|
| | | | 12,500 | | | | | | 17.94 | | |
Morris Rosenberg
|
| | | | 8/3/20 | | | |
Exercise of stock options
|
| | | | 6,987 | | | | | | 22.27 | | |
Morris Rosenberg
|
| | | | 8/4/20 | | | |
Exercise of stock options
|
| | | | 6,573 | | | | | | 15.68 | | |
Morris Rosenberg
|
| | | | 8/4/20 | | | |
Exercise of stock options
|
| | | | 9,192 | | | | | | 15.68 | | |
Morris Rosenberg
|
| | | | 8/6/20 | | | |
Exercise of stock options
|
| | | | 22,671 | | | | | | 15.68 | | |
Exhibit No.
|
| |
Description
|
|
(a)(1)(A) | | | Offer to Purchase, dated September 24, 2020 (incorporated by reference to Exhibit (a)(1)(A) to the Tender Offer Statement on the Schedule TO). | |
(a)(1)(B) | | | Form of Letter of Transmittal (incorporated by reference to Exhibit (a)(1)(B) to the Schedule TO). | |
(a)(1)(C) | | | Form of Notice of Guaranteed Delivery (incorporated by reference to Exhibit (a)(1)(C) to the Schedule TO). | |
(a)(1)(D) | | | Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to Exhibit (a)(1)(D) to the Schedule TO). | |
(a)(1)(E) | | | Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to Exhibit (a)(1)(E) to the Schedule TO). | |
(a)(1)(F) | | | Form of Summary Advertisement, published September 24, 2020 in The Wall Street Journal (incorporated by reference to Exhibit (a)(1)(F) to the Schedule TO). | |
(a)(5)(A) | | | Joint Press Release issued by Immunomedics, Inc. and Gilead Sciences, Inc., dated September 13, 2020 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed with the SEC by Immunomedics, Inc. on September 14, 2020). | |
(a)(5)(B) | | | Immunomedics, Inc. Announcement to Employees, first used on September 14, 2020 (incorporated by reference to Exhibit 99.1 to the Schedule 14D-9C filed with the SEC by Immunomedics, Inc. on September 14, 2020). | |
(a)(5)(C)* | | | Centerview Partners LLC Opinion Letter to the Company Board of Directors of Immunomedics, Inc., dated September 12, 2020 (included as Annex A to this Schedule 14D-9). | |
(a)(5)(D)* | | | BofA Securities, Inc. Opinion Letter to the Company Board of Directors of Immunomedics, Inc., dated September 12, 2020 (included as Annex B to this Schedule 14D-9). | |
(e)(1) | | | Agreement and Plan of Merger, dated as of September 13, 2020, by and among Immunomedics, Inc., Gilead Sciences, Inc. and Maui Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Form 8-K filed with the SEC by Immunomedics, Inc. on September 14, 2020). | |
(e)(2)* | | | Mutual Confidential Disclosure Agreement, effective as of January 1, 2019, by and between Immunomedics, Inc. and Gilead Sciences, Inc. | |
(e)(3)* | | | Amendment No. 1 to Mutual Confidential Disclosure Agreement, effective as of June 30, 2019, by and between Immunomedics, Inc. and Gilead Sciences, Inc. | |
(e)(4)* | | | Exclusivity Agreement, dated September 10, 2020, by and between Immunomedics, Inc. and Gilead Sciences, Inc. | |
(e)(5) | | | Definitive Proxy Statement of Immunomedics, Inc. on Schedule 14A (incorporated by reference to Immunomedics, Inc.’s Form DEF 14A filed April 27, 2020, as supplemented by additional materials filed with the SEC on Form DEFA 14A filed April 27, 2020 and May 27, 2020). | |
(e)(6) | | | Executive Employment Agreement, dated as of November 8, 2017, between the Company and Brendan Delaney (incorporated by reference to Exhibit 10.5 to the Company’s quarterly report on Form 10-Q, as filed with the SEC on February 8, 2018). | |
(e)(7) | | | Executive Employment Agreement, dated as of September 24, 2018, between the Company and Jared Freedberg (incorporated by reference to Exhibit 10.61 to the Company’s quarterly report on Form 10-Q, as filed with the SEC on November 7, 2018). | |
(e)(8) | | | Executive Employment Agreement, dated as of September 26, 2018, between the Company and Kurt Andrews (incorporated by reference to Exhibit 10.63 to the Company’s quarterly report on Form 10-Q, as filed with the SEC on November 7, 2018). | |
Exhibit No.
|
| |
Description
|
|
(e)(9) | | | Executive Employment Agreement, dated as of August 7, 2017, by and between the Company and Usama Malik (incorporated by reference to Exhibit 10.3 to the Company’s quarterly report on Form 10-Q, as filed with the SEC on May 9, 2019). | |
(e)(10)* | | | Executive Employment Agreement, dated as of February 25, 2019, by and between the Company and Bryan Ball. | |
(e)(11)* | | | Executive Employment Agreement, dated as of February 13, 2020, by and between the Company and Loretta Itri. | |
(e)(12)* | | | Executive Employment Agreement, dated as of March 30, 2020, by and between the Company and John Stubenrauch. | |
(e)(13)* | | | Make Whole Agreement, dated as of September 12, 2020, by and between Immunomedics, Inc. and Dr. Behzad Aghazadeh. | |
(e)(14)* | | | Amendment Agreement, dated as of September 12, 2020, by and between Immunomedics, Inc. and Brendan Delaney. | |
(e)(15)* | | | Amendment Agreement, dated as of September 12, 2020, by and between Immunomedics, Inc. and Bryan Ball. | |
(e)(16)* | | | Amendment Agreement, dated as of September 12, 2020, by and between Immunomedics, Inc. and Kurt Andrews. | |
(e)(17)* | | | Amendment Agreement, dated as of September 12, 2020, by and between Immunomedics, Inc. and Jared Freedberg. | |
(e)(18)* | | | Amendment Agreement, dated as of September 12, 2020, by and between Immunomedics, Inc. and Loretta Itri. | |
(e)(19)* | | | Amendment Agreement, dated as of September 12, 2020, by and between Immunomedics, Inc. and Usama Malik. | |
(e)(20)* | | | Amendment Agreement, dated as of September 12, 2020, by and between Immunomedics, Inc. and John Stubenrauch. | |
(e)(21) | | | Immunomedics, Inc. 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-8, as filed with the SEC on January 13, 2015). | |
(e)(22) | | | Forms of Incentive Stock Option Notice and Incentive Stock Option Agreement under the Immunomedics, Inc. 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.2 to the Registration Statement on Form S-8, as filed with the SEC on January 13, 2015). | |
(e)(23) | | | Forms of Nonqualified Stock Option Notice and Nonqualified Stock Option Agreement under the Immunomedics, Inc. 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.3 to the Registration Statement on Form S-8, as filed with the SEC on January 13, 2015). | |
(e)(24) | | | Forms of Restricted Stock Units Notice and Restricted Stock Units Agreement (for Officers/Employees) under the Immunomedics, Inc. 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.4 to the Registration Statement on Form S-8, as filed with the SEC on January 13, 2015). | |
(e)(25) | | | Forms of Restricted Stock Units Notice and Restricted Stock Units Agreement (for Directors) under the Immunomedics, Inc. 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.5 to the Registration Statement on Form S-8, as filed with the SEC on January 13, 2015). | |
(e)(26) | | | Immunomedics, Inc. Amended and Restated 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, as filed with the SEC on June 18, 2020). | |
Exhibit No.
|
| |
Description
|
|
(e)(27) | | | Forms of Incentive Stock Option Notice and Incentive Stock Option Agreement under the Immunomedics, Inc. Amended and Restated 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.49 to the Company’s quarterly report on Form 10-Q for the quarterly period ended June 30, 2020). | |
(e)(28) | | | Forms of Nonqualified Stock Option Notice and Nonqualified Stock Option Agreement under the Immunomedics, Inc. Amended and Restated 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.50 to the Company’s quarterly report on Form 10-Q for the quarterly period ended June 30, 2020). | |
(e)(29) | | | Forms of Restricted Stock Units Notice and Restricted Stock Units Agreement (for Officers/Employees) under the Immunomedics, Inc. Amended and Restated 2014 Long-Term Plan (incorporated by reference to Exhibit 10.51 to the Company’s quarterly report on Form 10-Q for the quarterly period ended June 30, 2020). | |
(e)(30) | | | Forms of Restricted Stock Units Notice and Restricted Stock Units Agreement (for Directors) under the Immunomedics, Inc. Amended and Restated 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.52 to the Company’s quarterly report on Form 10-Q for the quarterly period ended June 30, 2020). | |
(e)(31) | | | Amended and Restated Certificate of Incorporation of Immunomedics, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, as filed with the SEC on June 18, 2020). | |
(e)(32) | | | Amended and Restated Bylaws of Immunomedics, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, as filed with the SEC on April 17, 2019). | |
| Dated: September 24, 2020 | | |
By:
/s/ Usama Malik
|
|
| | | |
Name:
Usama Malik
|
|
| | | |
Title:
Chief Financial Officer
|
|
|
BofA Securities, Inc.
|
| |
GLOBAL CORPORATE &
INVESTMENT BANKING |
|
1 Year Immunomedics Chart |
1 Month Immunomedics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions